These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21347629)

  • 1. Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectives.
    ; Matsusaki K; Ohta K; Yoshizawa A; Gyoda Y
    Int J Clin Oncol; 2011 Aug; 16(4):395-400. PubMed ID: 21347629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of concentrated ascites reinfusion therapy (CART) for gynecological cancer patients with refractory massive ascites due to cancerous peritonitis.
    Togami S; Hori S; Kamio M; Matsuo T; Yoshinaga M; Douchi T
    Eur J Gynaecol Oncol; 2014; 35(3):301-3. PubMed ID: 24984546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A Case of Effective Palliative Care with CART for Refractory Ascites Associated with Cancerous Peritonitis of Gastric Cancer].
    Kawada J; Nishino M; Hata T; Ogino T; Hoshino H; Okano M; Nagai K; Kim Y; Okuyama M; Tsujinaka T
    Gan To Kagaku Ryoho; 2018 Apr; 45(4):700-702. PubMed ID: 29650840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A New Treatment Strategy-Novel Cell-Free and Concentrated Ascites Reinfusion System(KM-CART)for Massive Malignant Ascites].
    Matsusaki K
    Gan To Kagaku Ryoho; 2016 Dec; 43(13):2490-2497. PubMed ID: 28028255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occurrence of fever in cell-free and concentrated ascites reinfusion therapy is not related to the primary disease or nature of ascites.
    Fukunaga S; Egawa M; Ito T; Tanabe K
    J Artif Organs; 2024 Jun; 27(2):138-145. PubMed ID: 37178240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a novel automatic ascites filtration and concentration equipment with multi-ring-type roller pump units for cell-free and concentrated ascites reinfusion therapy.
    Okahisa T; Sogabe M; Nakagawa T; Tanaka K; Tomonari T; Taniguchi T; Takahashi A; Kinouchi Y; Nishioka J; Igata N; Yanagawa H; Komatsu T; Ohnishi Y; Fukuhara M; Ishikawa M; Shibata H; Shinomiya H; Nakasono M; Kishi F; Komai K; Tatsuki Y; Murashima T; Deguchi Y; Aramaki H; Fukumitsu H; Takayama T
    Artif Organs; 2020 Aug; 44(8):856-872. PubMed ID: 32187379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan.
    Yorioka N; Namisaki T; Shibamoto A; Suzuki J; Kubo T; Iwai S; Tomooka F; Tanaka M; Takeda S; Fujimoto Y; Enomoto M; Muarata K; Inoue T; Tsuji Y; Fujinaga Y; Nishimura N; Kitagawa K; Takaya H; Kaji K; Kawaratani H; Akahane T; Mitoro A; Yamazaki M; Yoshiji H
    In Vivo; 2023; 37(3):1226-1235. PubMed ID: 37103093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience.
    Tsubokura M; Adegawa Y; Kojima M; Tanosaki R; Ohtake R; Kase Y; Iwashita N; Kasane M; Nakabayashi S; Takeuchi S; Kato K; Boku N; Kanemitsu Y; Okusaka T; Fujimoto H; Yonemori K; Ishiki H; Kawamura K; Satomi E; Matsushita H
    BMC Cancer; 2022 Mar; 22(1):268. PubMed ID: 35287609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of Patients and Their Ascites Who Underwent Repeated Cell-Free and Concentrated Ascites Reinfusion Therapy.
    Maeda S; Yabuuchi J; Nobuta H; Makiishi T; Hirose K
    Ther Apher Dial; 2015 Aug; 19(4):342-8. PubMed ID: 26386222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-Free and Concentrated Ascites Reinfusion Therapy for Decompensated Liver Cirrhosis.
    Kozaki K; IInuma M; Takagi T; Fukuda T; Sanpei T; Terunuma Y; Yatabe Y; Akano K
    Ther Apher Dial; 2016 Aug; 20(4):376-82. PubMed ID: 27523078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cell-Free Ascites Reinfusion Therapy(CART)Modified by Keisuke Matsusaki(KM-CART)at Our Hospital].
    Iwaki R; Shindo K; Kawahara H; Nanba N; Kuramoto Y; Beppu T; Uesugi T; Tanaka Y; Uesugi Y
    Gan To Kagaku Ryoho; 2018 Dec; 45(13):2165-2167. PubMed ID: 30692319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility, efficacy, and safety of cell-free and concentrated ascites reinfusion therapy (KM-CART) for malignant ascites.
    Matsusaki K; Orihashi K
    Artif Organs; 2020 Oct; 44(10):1090-1097. PubMed ID: 32242939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single center experience of cell-free and concentrated ascites reinfusion therapy in malignancy related ascites.
    Ito T; Hanafusa N; Fukui M; Yamamoto H; Watanabe Y; Noiri E; Iwase S; Miyagawa K; Fujita T; Nangaku M
    Ther Apher Dial; 2014 Feb; 18(1):87-92. PubMed ID: 24499089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of Major Problems in the Cell-Free and Concentrated Ascites Reinfusion Therapy System─Constructing of Cell-Free and Concentrated Ascites Reinfusion Therapy System Using External Pressure for Filtration.
    Yoshizawa M; Nakatsuji Y
    Ther Apher Dial; 2019 Jun; 23(3):233-236. PubMed ID: 31033153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.
    Hanafusa N; Isoai A; Ishihara T; Inoue T; Ishitani K; Utsugisawa T; Yamaka T; Ito T; Sugiyama H; Arakawa A; Yamada Y; Itano Y; Onodera H; Kobayashi R; Torii N; Numata T; Kashiwabara T; Matsuno Y; Kato M
    PLoS One; 2017; 12(5):e0177303. PubMed ID: 28510606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
    Yamaguchi H; Kitayama J; Emoto S; Ishigami H; Ito T; Hanafusa N; Watanabe T
    Eur J Surg Oncol; 2015 Jul; 41(7):875-80. PubMed ID: 25986856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites.
    Kawata Y; Nagasaka K; Matsumoto Y; Oda K; Tanikawa M; Sone K; Mori-Uchino M; Tsuruga T; Arimoto T; Osuga Y; Fujii T
    Int J Clin Oncol; 2019 Apr; 24(4):420-427. PubMed ID: 30474762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.
    Hanada R; Yokomichi N; Kato C; Miki K; Oyama S; Morita T; Kawahara R
    Support Care Cancer; 2018 May; 26(5):1489-1497. PubMed ID: 29168037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technical Performance and Clinical Effectiveness of Drop Type With Adjustable Concentrator-Cell Free and Concentrated Ascites Reinfusion Therapy.
    Yamada Y; Harada M; Yamaguchi A; Kobayashi Y; Chino T; Minowa T; Kosuge T; Tsukada W; Hashimoto K; Kamijo Y
    Artif Organs; 2017 Dec; 41(12):1135-1144. PubMed ID: 28589706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascitic IL-10 Concentration Predicts Prognosis of Patients Undergoing Cell-Free and Concentrated Ascites Reinfusion Therapy.
    Ito T; Hanafusa N; Iwase S; Noiri E; Nangaku M; Nakagawa K; Miyagawa K
    Ther Apher Dial; 2020 Feb; 24(1):90-95. PubMed ID: 31157953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.